PMID- 35720006
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - IGH Translocations in Chinese Patients With Chronic Lymphocytic Leukemia: 
      Clinicopathologic Characteristics and Genetic Profile.
PG  - 858523
LID - 10.3389/fonc.2022.858523 [doi]
LID - 858523
AB  - Immunoglobulin heavy chain translocations (IGH-t) have occasionally been reported 
      in Chinese patients with chronic lymphocytic leukemia (CLL). The objective of the 
      present study was to identify the clinicopathologic features of patients with 
      IGH-t CLL and compare them with those of patients with non-IGH-t CLL. We 
      performed fluorescence in situ hybridization (FISH) based on a routine CLL 
      prognostic FISH panel using IGH, IGH-BCL2, BCL3, IGH-CMYC, and BCL6 FISH probes. 
      Furthermore, we retrospectively evaluated the clinical features of 138 newly 
      diagnosed CLL patients via chromosome banding analysis (CBA), FISH, and targeted 
      next-generation sequencing. IGH-t was identified in 25 patients (18.1%). Patients 
      with IGH-t CLL had lower flow scores than those with non-IGH-t CLL. The most 
      frequent translocation was t(14;18) (10 patients), followed by t(14;19) (3 
      patients), and t(2;14)(p13;q32), t(7;14)(q21.2;q12), t(9;14)(p13;q32) (3 
      patients). The remaining nine patients included three with abnormal karyotypes 
      without translocation involving 14q32, four with a normal karyotype, and two who 
      failed CBA. The most frequently concomitant FISH-detected aberrations were 13q 
      deletion, followed by +12 and TP53 deletion, while one case involved ATM 
      deletion. Complex karyotypes were detected in five patients with IGH-t CLL, in 
      whom all partner genes were non-BCL2. Available mutational information indicated 
      that KMT2D mutation was the most frequent mutation among tested 70 patients, 
      while TP53 mutation was the most frequent mutation in the IGH-t group. Moreover, 
      the IGH-t group had higher FBXW7 (P=0.014) and ATM (P=0.004) mutations than the 
      non-IGH-t group, and this difference was statistically significant. Our study 
      demonstrates that IGH-t is not uncommon among Chinese CLL patients, and that its 
      partner genes are multiple. The gene mutational profile of the IGH-t group was 
      distinct from that of the non-IGH-t group, and the concomitant chromosomal 
      abnormalities within the IGH-t CLL group differed. Thus, identification of IGH-t 
      and its partner genes in CLL patients may help further refine risk stratification 
      and strengthen the accurate management in CLL patients.
CI  - Copyright (c) 2022 Li, Xing, Zhang, Mao, Xiao and Wang.
FAU - Li, Qinlu
AU  - Li Q
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Xing, Shugang
AU  - Xing S
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Zhang, Heng
AU  - Zhang H
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Mao, Xiao
AU  - Mao X
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Xiao, Min
AU  - Xiao M
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
DEP - 20220602
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9201519
OTO - NOTNLM
OT  - IGH translocation
OT  - chronic lymphocytic leukemia
OT  - clinical molecular genetics
OT  - cytogenetics
OT  - next-generation sequencing
OT  - prognostic biomarkers
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/21 06:00
MHDA- 2022/06/21 06:01
PMCR- 2022/01/01
CRDT- 2022/06/20 03:37
PHST- 2022/01/20 00:00 [received]
PHST- 2022/05/05 00:00 [accepted]
PHST- 2022/06/20 03:37 [entrez]
PHST- 2022/06/21 06:00 [pubmed]
PHST- 2022/06/21 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.858523 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jun 2;12:858523. doi: 10.3389/fonc.2022.858523. eCollection 
      2022.